Put Albrioza’s Role for Amyotrophic Lateral Sclerosis in Perspective
September 2022
Canada is the first country to approve Albrioza, a new oral med for amyotrophic lateral sclerosis (ALS).
It contains sodium phenylbutyrate and ursodoxicoltaurine.
Radicava (edaravone) IV infusion and riluzole oral tabs are the only other meds approved to treat this rare, progressive, degenerative nerve disease...also known as Lou Gehrig’s disease.Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive